| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL3A1 |
| Uniprot No | P02461 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1059-1466aa |
| 氨基酸序列 | GK SGDRGESGPA GPAGAPGPAG SRGAPGPQGP RGDKGETGER GAAGIKGHRG FPGNPGAPGS PGPAGQQGAI GSPGPAGPRG PVGPSGPPGK DGTSGHPGPI GPPGPRGNRG ERGSEGSPGH PGQPGPPGPP GAPGPCCGGV GAAAIAGIGG EKAGGFAPYY GDEPMDFKIN TDEIMTSLKS VNGQIESLIS PDGSRKNPAR NCRDLKFCHP ELKSGEYWVD PNQGCKLDAI KVFCNMETGE TCISANPLNV PRKHWWTDSS AEKKHVWFGE SMDGGFQFSY GNPELPEDVL DVHLAFLRLL SSRASQNITY HCKNSIAYMD QASGNVKKAL KLMGSNEGEF KAEGNSKFTY TVLEDGCTKH TGEWSKTVFE YRTRKAVRLP IVDIAPYDIG GPDQEFGVDV GPVCFL |
| 预测分子量 | 72 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL3A1重组蛋白的3篇示例文献摘要(虚构示例，仅供格式参考)：
---
1. **"Recombinant COL3A1 expression in HEK293 cells reveals impaired secretion of vascular Ehlers-Danlos syndrome mutants"**
*Authors: Smith A, et al.*
**摘要**：本研究在HEK293细胞中表达了野生型和致病突变型COL3A1重组蛋白，发现突变体因内质网滞留导致分泌减少，解释了血管脆性疾病的分子机制。
2. **"Structural characterization of recombinant human COL3A1 fibrils using cryo-EM"**
*Authors: Johnson B, et al.*
**摘要**：通过昆虫细胞系统表达并纯化COL3A1重组蛋白，利用冷冻电镜解析其三螺旋结构，为靶向胶原异常的药物设计提供结构基础。
3. **"Recombinant COL3A1-functionalized scaffolds enhance wound healing in murine models"**
*Authors: Lee C, et al.*
**摘要**：将重组COL3A1蛋白整合到生物材料支架中，实验显示其显著促进成纤维细胞迁移和血管生成，提示在皮肤再生中的应用潜力。
---
*注：以上文献为示例性质，实际研究中请通过学术数据库(如PubMed)检索真实发表的文章。*
The COL3A1 gene encodes the pro-α1 chain of type III collagen, a fibrillar collagen critical for maintaining structural integrity and elasticity in tissues. As a key component of the extracellular matrix (ECM), type III collagen is predominantly found in skin, blood vessels, and hollow organs, where it forms heterotypic fibrils with type I collagen. COL3A1 recombinant protein is produced in vitro using recombinant DNA technology, typically expressed in bacterial, insect, or mammalian systems to ensure proper post-translational modifications, particularly hydroxylation of proline and lysine residues essential for triple-helix formation.
This recombinant protein serves as a vital tool for studying collagen biosynthesis, ECM remodeling, and cell-matrix interactions. Researchers utilize it to model connective tissue disorders, particularly vascular Ehlers-Danlos syndrome (vEDS), which is linked to COL3A1 mutations causing defective collagen III synthesis. Its applications extend to tissue engineering, where it aids in constructing biomimetic scaffolds for wound healing and vascular grafts. In drug development, it enables screening of antifibrotic agents targeting collagen overproduction in fibrotic diseases.
Structural studies using COL3A1 recombinant protein have revealed insights into collagen network assembly and mechanotransduction pathways. Its interaction with integrins and other ECM components is crucial for understanding tissue elasticity and angiogenesis. Challenges in production include maintaining thermal stability and preventing premature aggregation, often addressed through codon optimization and co-expression with modifying enzymes. Validated via SDS-PAGE, circular dichroism, and cell adhesion assays, this recombinant protein remains indispensable for both basic research and therapeutic exploration in connective tissue pathologies.
×
